339 related articles for article (PubMed ID: 19512976)
1. Decreased activation along the dorsal visual pathway after a 3-month treatment with galantamine in mild Alzheimer disease: a functional magnetic resonance imaging study.
Bokde AL; Karmann M; Teipel SJ; Born C; Lieb M; Reiser MF; Möller HJ; Hampel H
J Clin Psychopharmacol; 2009 Apr; 29(2):147-56. PubMed ID: 19512976
[TBL] [Abstract][Full Text] [Related]
2. Cholinergic challenge in Alzheimer patients and mild cognitive impairment differentially affects hippocampal activation--a pharmacological fMRI study.
Goekoop R; Scheltens P; Barkhof F; Rombouts SA
Brain; 2006 Jan; 129(Pt 1):141-57. PubMed ID: 16251213
[TBL] [Abstract][Full Text] [Related]
3. Challenging the cholinergic system in mild cognitive impairment: a pharmacological fMRI study.
Goekoop R; Rombouts SA; Jonker C; Hibbel A; Knol DL; Truyen L; Barkhof F; Scheltens P
Neuroimage; 2004 Dec; 23(4):1450-9. PubMed ID: 15589109
[TBL] [Abstract][Full Text] [Related]
4. Functional connectivity of the fusiform gyrus during a face-matching task in subjects with mild cognitive impairment.
Bokde AL; Lopez-Bayo P; Meindl T; Pechler S; Born C; Faltraco F; Teipel SJ; Möller HJ; Hampel H
Brain; 2006 May; 129(Pt 5):1113-24. PubMed ID: 16520329
[TBL] [Abstract][Full Text] [Related]
5. Morphological substrate of face matching in healthy ageing and mild cognitive impairment: a combined MRI-fMRI study.
Teipel SJ; Bokde AL; Born C; Meindl T; Reiser M; Möller HJ; Hampel H
Brain; 2007 Jul; 130(Pt 7):1745-58. PubMed ID: 17566054
[TBL] [Abstract][Full Text] [Related]
6. Functional abnormalities of the visual processing system in subjects with mild cognitive impairment: an fMRI study.
Bokde AL; Lopez-Bayo P; Born C; Dong W; Meindl T; Leinsinger G; Teipel SJ; Faltraco F; Reiser M; Möller HJ; Hampel H
Psychiatry Res; 2008 Aug; 163(3):248-59. PubMed ID: 18672352
[TBL] [Abstract][Full Text] [Related]
7. Regional brain activity after prolonged cholinergic enhancement in early Alzheimer's disease.
Shanks MF; McGeown WJ; Forbes-McKay KE; Waiter GD; Ries M; Venneri A
Magn Reson Imaging; 2007 Jul; 25(6):848-59. PubMed ID: 17442521
[TBL] [Abstract][Full Text] [Related]
8. Alzheimer disease: functional abnormalities in the dorsal visual pathway.
Bokde AL; Lopez-Bayo P; Born C; Ewers M; Meindl T; Teipel SJ; Faltraco F; Reiser MF; Möller HJ; Hampel H
Radiology; 2010 Jan; 254(1):219-26. PubMed ID: 20032154
[TBL] [Abstract][Full Text] [Related]
9. A 2-year open-label study of galantamine therapy in Chinese Alzheimer's disease patients in Hong Kong.
Chu LW; Yik PY; Mok W; Chung CP
Int J Clin Pract; 2007 Mar; 61(3):403-10. PubMed ID: 17313606
[TBL] [Abstract][Full Text] [Related]
10. Increased glutamate in the hippocampus after galantamine treatment for Alzheimer disease.
Penner J; Rupsingh R; Smith M; Wells JL; Borrie MJ; Bartha R
Prog Neuropsychopharmacol Biol Psychiatry; 2010 Feb; 34(1):104-10. PubMed ID: 19833161
[TBL] [Abstract][Full Text] [Related]
11. Treatment effects of therapeutic cholinesterase inhibitors on visuospatial processing in Alzheimer's disease: a longitudinal functional MRI study.
Thiyagesh SN; Farrow TF; Parks RW; Accosta-Mesa H; Hunter MD; Young C; Wilkinson ID; Woodruff PW
Dement Geriatr Cogn Disord; 2010; 29(2):176-88. PubMed ID: 20215749
[TBL] [Abstract][Full Text] [Related]
12. Metabolic patterns associated with the clinical response to galantamine therapy: a fludeoxyglucose f 18 positron emission tomographic study.
Mega MS; Dinov ID; Porter V; Chow G; Reback E; Davoodi P; O'Connor SM; Carter MF; Amezcua H; Cummings JL
Arch Neurol; 2005 May; 62(5):721-8. PubMed ID: 15883258
[TBL] [Abstract][Full Text] [Related]
13. Update on Alzheimer drugs (galantamine).
Raskind MA
Neurologist; 2003 Sep; 9(5):235-40. PubMed ID: 12971834
[TBL] [Abstract][Full Text] [Related]
14. The effect of Galantamine on sleep quality in Thai Alzheimer's disease patients.
Chankrachang S; Senanarong V; Poungvarin N; Phanthumchinda K; Tavichachart N; Praditsuwan R; Nidhinandana S
J Med Assoc Thai; 2008 Sep; 91(9):1343-9. PubMed ID: 18843862
[TBL] [Abstract][Full Text] [Related]
15. Differences between Alzheimer's disease and dementia with Lewy bodies: an fMRI study of task-related brain activity.
Sauer J; ffytche DH; Ballard C; Brown RG; Howard R
Brain; 2006 Jul; 129(Pt 7):1780-8. PubMed ID: 16670180
[TBL] [Abstract][Full Text] [Related]
16. Failure to modulate neural response to increased task demand in mild Alzheimer's disease: fMRI study of visuospatial processing.
Vannini P; Lehmann C; Dierks T; Jann K; Viitanen M; Wahlund LO; Almkvist O
Neurobiol Dis; 2008 Sep; 31(3):287-97. PubMed ID: 18619845
[TBL] [Abstract][Full Text] [Related]
17. Reduced neuronal efficacy in progressive mild cognitive impairment: a prospective fMRI study on visuospatial processing.
Vannini P; Almkvist O; Dierks T; Lehmann C; Wahlund LO
Psychiatry Res; 2007 Oct; 156(1):43-57. PubMed ID: 17719211
[TBL] [Abstract][Full Text] [Related]
18. Early onset effects of galantamine treatment on attention in patients with Alzheimer's disease.
Vellas B; Cunha L; Gertz HJ; De Deyn PP; Wesnes K; Hammond G; Schwalen S;
Curr Med Res Opin; 2005 Sep; 21(9):1423-9. PubMed ID: 16197661
[TBL] [Abstract][Full Text] [Related]
19. Cholinergic enhancement of frontal lobe activity in mild cognitive impairment.
Saykin AJ; Wishart HA; Rabin LA; Flashman LA; McHugh TL; Mamourian AC; Santulli RB
Brain; 2004 Jul; 127(Pt 7):1574-83. PubMed ID: 15140813
[TBL] [Abstract][Full Text] [Related]
20. [Galantamine: a novel cholinergic agent for Alzheimer's disease].
Olazarán J; García G
Neurologia; 2002 Oct; 17(8):429-36. PubMed ID: 12396973
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
